BioWorld

Jan. 8, 2002

Chiron Buying Matrix For $61M, Adding Tezacitabine To Pipeline

Chiron Corp., its eyes firmly focused on the cancer therapeutic tezacitabine, is acquiring Matrix Pharmaceutical Inc. for $61 million in cash. Read More

Alexion Starts Phase III Study With Heart Drug Pexelizumab

Rodents Modeling Parkinson s Disease Generate Dopaminergic Neurons To Stem Losses In PD

Tripos Collaborates With Pfizer To Help Build Compound Library

Other News To Note

Structural GenomiX Partners With Millennium, Aventis For Discovery

Alteon Raising $18.6M To Fund Discovery, Development Work

Genencor, Seattle Genetics Align To Develop Cancer Therapeutics

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

BioWorld

Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...